Can we administer Acetazolamide in patients with heart failure? A systematic review
DOI:
https://doi.org/10.56294/dm202212Keywords:
Heart Failure, Acetazolamide, Congestion, Diuretics, Pharmacological ActionAbstract
Introduction: heart failure (HF) is a clinical syndrome characterized by a variety of symptoms and signs due to structural and/or functional abnormalities of the heart leading to decreased heart rate, cardiac output and/or increased intracardiac pressures. Studies suggest that acetazolamide could improve the efficacy of ASA diuretics, which could lead to improved natriuresis and diuresis.
Aims: to evaluate the effectiveness of acetazolamide in improving congestion symptoms in patients with Heart Failure.
Methods: a systematic review will be carried out, following the PRISMA methodology, which will include a search in Pubmed, Scopus, Web of Science databases without time restriction.
Results: 5 studies were included, of which 4 were clinical trials.
Conclusions: after comprehensive and detailed analysis of the included studies, we found limited evidence suggesting that the use of acetazolamide may be effective in the treatment of heart failure, especially as additional or complementary therapy to other treatments. However, it is important to keep in mind that the results of the pilot studies are limited and that more research is required to fully evaluate the efficacy and safety of acetazolamide in the treatment of heart failure. The use of acetazolamide in patients with heart failure may be controversial and requires careful evaluation of clinical risks and benefits before it is considered as a treatment
References
1. Kurmani S, Squire I. Acute Heart Failure: Definition, Classification and Epidemiology. Curr Heart Fail Rep 2017;14:385-92. https://doi.org/10.1007/s11897-017-0351-y.
2. Snipelisky D, Chaudhry S-P, Stewart GC. The Many Faces of Heart Failure. Card Electrophysiol Clin 2019;11:11-20. https://doi.org/10.1016/j.ccep.2018.11.001.
3. Robles Gamboa C. Insuficiencia cardíaca crónica. Medicine - Programa de Formación Médica Continuada Acreditado 2017;12:2100-15. https://doi.org/10.1016/j.med.2017.06.003.
4. Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K, et al. Acute heart failure. Nat Rev Dis Primers 2020;6:1-15. https://doi.org/10.1038/s41572-020-0151-7.
5. Sinnenberg L, Givertz MM. Acute heart failure. Trends in Cardiovascular Medicine 2020;30:104-12. https://doi.org/10.1016/j.tcm.2019.03.007.
6. Monroy LE, Vargas MPS. Anhidrasa carbónica, nuevas perspectivas. Neumol Cir Torax 2010;69:200-9.
7. McKenna R, Supuran CT. Carbonic anhydrase inhibitors drug design. Subcell Biochem 2014;75:291-323. https://doi.org/10.1007/978-94-007-7359-2_15.
8. Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709-12. https://doi.org/10.1080/13543776.2018.1523897.
9. Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, et al. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail 2018;20:1591-600. https://doi.org/10.1002/ejhf.1307.
10. Acar S, Sanli S, Oztosun C, Afsar B, Sag AA, Kuwabara M, et al. Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. Int Urol Nephrol 2021;53:1839-49. https://doi.org/10.1007/s11255-020-02704-7.
11. Cimolai N. Acetazolamide and Cardiac Failure. Clin Drug Investig 2018;38:649-50. https://doi.org/10.1007/s40261-018-0653-1.
12. Cimolai N. Acetazolamide and Cardiac Failure. Clin Drug Investig 2018;38:649-50. https://doi.org/10.1007/s40261-018-0653-1.
13. Cuthbert JJ, Bhandari S, Clark AL. Hypochloraemia in Patients with Heart Failure: Causes and Consequences. Cardiol Ther 2020;9:333-47. https://doi.org/10.1007/s40119-020-00194-3.
14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas. Revista Española de Cardiología 2021;74:790-9. https://doi.org/10.1016/j.recesp.2021.06.016.
15. Kataoka H. Acetazolamide as a potent chloride-regaining diuretic: short- and long-term effects, and its pharmacologic role under the ‘chloride theory’ for heart failure pathophysiology. Heart Vessels 2019;34:1952-60. https://doi.org/10.1007/s00380-019-01433-x.
16. Imiela T, Budaj A. Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study. Clin Drug Investig 2017;37:1175-81. https://doi.org/10.1007/s40261-017-0577-1.
17. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med 2022;387:1185-95. https://doi.org/10.1056/NEJMoa2203094.
18. Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. European Journal of Heart Failure 2019;21:1415-22. https://doi.org/10.1002/ejhf.1478.
19. Javaheri S. Acetazolamide Improves Central Sleep Apnea in Heart Failure. Am J Respir Crit Care Med 2006;173:234-7. https://doi.org/10.1164/rccm.200507-1035OC.
20. Kataoka H. Comparison of Changes in Plasma Volume and Renal Function between Acetazolamide and Conventional Diuretics: Understanding the Mechanical Differences according to the “Chloride Theory”. CRD 2020;145:215-23. https://doi.org/10.1159/000504533
Published
Issue
Section
License
Copyright (c) 2022 Maria Eduarda Santos Luna (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
